AROA in the News

06 April 2021
Aroa Biosurgery secures FDA clearance for new product, Myriad Morcells™, offering highly conformable tissue regeneration in wound beds

HIGHLIGHTS U.S. FDA 510(k) clearance received for a new Aroa Biosurgery product named Myriad Morcells™, a morcellized (powder) format of…

16 February 2021
Pilot study indicated benefits of Aroa Biosurgery’s Myriad™ in surgical reconstruction of chronic wounds

HIGHLIGHTS Aroa’s Myriad™ may be used successfully under a tissue flap to reduce surgical complications in the flap reconstruction of…

02 February 2021
Aroa Biosurgery to further expand fully dedicated sales team for key U.S. market

HIGHLIGHTS Aroa to expand on its own direct field sales presence in the United States market in a move expected…

More from AROA

16 December 2020
New study shows Aroa Biosurgery’s Myriad™ efficacy in healing exposed vital body structures

HIGHLIGHTS Aroa’s Myriad™ is further validated in a clinical study and peer-reviewed publication – Journal of Wound Care.Study shows 100%…

Read More
09 December 2020
Indian regulatory approval received for three Aroa products

HIGHLIGHTS The national regulatory authority of India, the Central Drugs Standard Control Organisation (CDSCO), approves Myriad™, Endoform® Natural and Endoform®…

Read More
12 November 2020
Aroa Biosurgery’s Myriad™ shown to be effective in surgical treatment of Hidradenitis Suppurativa

HIGHLIGHTS Further validation for Aroa’s MyriadTM from clinical study and peer-reviewed publication in Journal of Wound Care.Study shows high success…

Read More
19 August 2020
Aroa Biosurgery’s Endoform® platform shown to attract stem cells

HIGHLIGHTS Further validation gained for Aroa’s proprietary Endoform® platform with peer-reviewed publication in PLOS ONE.Study provides further insights on the…

Read More
30 July 2020
European approval received for Myriad™

HIGHLIGHTS CE Mark to allow commercialization of Aroa’s Myriad™ product in the EUMyriad™ is designed for dermal soft tissue reconstruction…

Read More
30 July 2020
Aroa Biosurgery secures FDA Clearance for Symphony™

HIGHLIGHTS U.S. FDA clearance received for a new Aroa Biosurgery product Symphony™, designed to support healing during the proliferative phase…

Read More
23 June 2020
Aroa Biosurgery to list on the ASX in $225m IPO

Auckland-based soft tissue regeneration company Aroa Biosurgery Limited (Aroa) is set to list on the Australian Securities Exchange (ASX) as…

Read More
31 March 2020
Aroa Biosurgery opens new pathway for advanced wound treatment amidst COVID-19 disruption in the United States

San Diego, U.S. Soft tissue repair company Aroa Biosurgery is stepping up to support clinicians and their patients who are…

Read More
25 March 2020
COVID-19 Update – Aroa Biosurgery is well placed to maintain supply of Endoform® and Myriad™ products to clinicians and patients

Aroa Biosurgery is taking the appropriate precautions and measures amid a rapidly changing global picture for COVID-19 virus. CEO Brian…

Read More
Developed by New Zealand Website Design